Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study☆
| Autor: | Gerald J. Gleich, Hirohito Kita, Loren W. Hunt, Evangelo Frigas, Joseph H. Butterfield, S. L. Dunnette, Kenneth P. Offord, Judith Blomgren |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Adolescent Lidocaine medicine.drug_class Immunology Placebo-controlled study Placebo law.invention Leukocyte Count Randomized controlled trial law Forced Expiratory Volume Bronchodilator Administration Inhalation medicine Humans Immunology and Allergy Anti-Asthmatic Agents Glucocorticoids Asthma Inhalation business.industry Nebulizers and Vaporizers Middle Aged medicine.disease Eosinophils Anesthesia Female Safety business Glucocorticoid medicine.drug |
| Zdroj: | Journal of Allergy and Clinical Immunology. 113:853-859 |
| ISSN: | 0091-6749 |
| DOI: | 10.1016/j.jaci.2004.02.039 |
| Popis: | Background In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective We tested the safety and efficacy of nebulized lidocaine in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV 1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV 1 ( P ≤ .001), nighttime awakenings ( P ≤ .02), symptoms ( P ≤ .010), bronchodilator use ( P ≤ .010), and blood eosinophil counts ( P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use ( P ≤ .05 for both), and blood eosinophil counts ( P ≤ .01) and decreases in FEV 1 ( P ≤ .001). Conclusion Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect